Day One Biopharmaceuticals Inc

NASDAQ DAWN

Download Data

Day One Biopharmaceuticals Inc Current Ratio 2 year CAGR for the quarter ending March 31, 2024: -42.20%

Day One Biopharmaceuticals Inc Current Ratio 2 year CAGR is -42.20% for the quarter ending March 31, 2024, a 11.72% change year over year. The current ratio assesses a company's short-term liquidity and its ability to cover its current liabilities with its current assets. It is calculated by dividing current assets by current liabilities. This ratio indicates the number of times a company's current assets can cover its current liabilities. A higher current ratio suggests better liquidity and a stronger ability to meet short-term obligations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Day One Biopharmaceuticals Inc Current Ratio for the quarter ending March 31, 2023 was 14.11, a -56.85% change year over year.
  • Day One Biopharmaceuticals Inc Current Ratio for the quarter ending March 31, 2022 was 32.70, a -36.84% change year over year.
  • Day One Biopharmaceuticals Inc Current Ratio for the quarter ending March 31, 2021 was 51.78.
NASDAQ: DAWN

Day One Biopharmaceuticals Inc

CEO Dr. Jeremy Bender M.B.A., Ph.D.
IPO Date May 27, 2021
Location United States
Headquarters 395 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Employees 174
Sector Healthcare
Industry Biotechnology
Description

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Similar companies

ABOS

Acumen Pharmaceuticals Inc

NA

NA

ELDN

Eledon Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email